Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

4,897 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunotherapy of Ipilimumab and Nivolumab in Patients with Advanced Neuroendocrine Tumors: A Subgroup Analysis of the CA209-538 Clinical Trial for Rare Cancers.
Klein O, Kee D, Markman B, Michael M, Underhill C, Carlino MS, Jackett L, Lum C, Scott C, Nagrial A, Behren A, So JY, Palmer J, Cebon J. Klein O, et al. Among authors: palmer j. Clin Cancer Res. 2020 Sep 1;26(17):4454-4459. doi: 10.1158/1078-0432.CCR-20-0621. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532787 Clinical Trial.
Evaluation of Combination Nivolumab and Ipilimumab Immunotherapy in Patients With Advanced Biliary Tract Cancers: Subgroup Analysis of a Phase 2 Nonrandomized Clinical Trial.
Klein O, Kee D, Nagrial A, Markman B, Underhill C, Michael M, Jackett L, Lum C, Behren A, Palmer J, Tebbutt NC, Carlino MS, Cebon J. Klein O, et al. Among authors: palmer j. JAMA Oncol. 2020 Sep 1;6(9):1405-1409. doi: 10.1001/jamaoncol.2020.2814. JAMA Oncol. 2020. PMID: 32729929 Free PMC article. Clinical Trial.
Combination immunotherapy with nivolumab and ipilimumab in patients with rare gynecological malignancies: results of the CA209-538 clinical trial.
Klein O, Kee D, Gao B, Markman B, da Gama Duarte J, Quigley L, Jackett L, Linklater R, Strickland A, Scott C, Mileshkin L, Palmer J, Carlino M, Behren A, Cebon J. Klein O, et al. Among authors: palmer j. J Immunother Cancer. 2021 Nov;9(11):e003156. doi: 10.1136/jitc-2021-003156. J Immunother Cancer. 2021. PMID: 34782426 Free PMC article. Clinical Trial.
A gut microbial signature for combination immune checkpoint blockade across cancer types.
Gunjur A, Shao Y, Rozday T, Klein O, Mu A, Haak BW, Markman B, Kee D, Carlino MS, Underhill C, Frentzas S, Michael M, Gao B, Palmer J, Cebon J, Behren A, Adams DJ, Lawley TD. Gunjur A, et al. Among authors: palmer j. Nat Med. 2024 Mar;30(3):797-809. doi: 10.1038/s41591-024-02823-z. Epub 2024 Mar 1. Nat Med. 2024. PMID: 38429524 Free PMC article.
Personalized Approach to Olfactory Neuroblastoma Care.
Lerner DK, Palmer JN. Lerner DK, et al. Among authors: palmer jn. J Pers Med. 2024 Apr 16;14(4):423. doi: 10.3390/jpm14040423. J Pers Med. 2024. PMID: 38673050 Free PMC article. Review.
4,897 results